Literature DB >> 8665086

Pathogenic potential of myeloblastosis-associated viruses.

B Perbal1.   

Abstract

Myeloblastosis-associated viruses (MAV) are replication competent avian retroviruses responsible for the induction of lymphoid leukosis, osteopetrosis, and nephroblastoma. Although both the route of infection and the strain of host used has been reported to be a critical factor in determining the outcome of viral infection, genetically distinct strains of MAV that exhibit a multiple pathogenic potential have been molcularly cloned. Osteopetrosis is a proliferative disease of the bones and nephroblastoma is a kidney cancer. Both diseases occur in chickens a few weeks after MAV injection. In both cases, the nature of the target cells and mechanisms of transformation induced by MAV remain to be established. Molecular cloning and sequencing of three MAV proviral genomes inducing both osteopetrosis and nephroblastoma or only nephroblastoma have allowed the identification of viral determinants essential for osteopetrosis induction. For the last decade we have focused our attention on the MAV-induced nephroblastoma because it is a unique animal model of the human Wilms' tumor. Studies that we have conducted to understand the molecular basis of MAV tumorigenic potential have led to the identification of viral sequences required for tumor induction and to the discovery of a new cellular gene (nov) likely to play a critical role in avian and human nephroblastoma development.

Entities:  

Mesh:

Year:  1995        PMID: 8665086

Source DB:  PubMed          Journal:  Infect Agents Dis        ISSN: 1056-2044


  10 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  The noncoding and surface envelope coding sequences of myeloblastosis-associated virus are respectively responsible for nephroblastoma development and renal hyperplasia.

Authors:  V Joliot; C Khelifi; M Wyers; G Dambrine; F Lasserre; P Lemercier; B Perbal
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

3.  Effects of resveratrol and its analogue pterostilbene, on NOV/CCN3 adipokine in adipose tissue from rats fed a high-fat high-sucrose diet.

Authors:  J Trepiana; S Gómez-Zorita; Alfredo Fernández-Quintela; M González; M P Portillo
Journal:  J Physiol Biochem       Date:  2019-04-11       Impact factor: 4.158

4.  The CCN family of proteins: a 25th anniversary picture.

Authors:  Annick Perbal; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2016-08-31       Impact factor: 5.782

5.  Nuclear localisation of NOVH protein: a potential role for NOV in the regulation of gene expression.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  1999-04

6.  Integration of Myeloblastosis Associated Virus proviral sequences occurs in the vicinity of genes encoding signaling proteins and regulators of cell proliferation.

Authors:  Chang Long Li; Philippe Coullin; Alain Bernheim; Véronique Joliot; Charles Auffray; Rima Zoroob; Bernard Perbal
Journal:  Cell Commun Signal       Date:  2006-01-10       Impact factor: 5.712

7.  NOV story: the way to CCN3.

Authors:  Bernard Perbal
Journal:  Cell Commun Signal       Date:  2006-02-20       Impact factor: 5.712

Review 8.  Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development.

Authors:  Xavier Escoté; Saioa Gómez-Zorita; Miguel López-Yoldi; Iñaki Milton-Laskibar; Alfredo Fernández-Quintela; J Alfredo Martínez; María J Moreno-Aliaga; María P Portillo
Journal:  Int J Mol Sci       Date:  2017-08-15       Impact factor: 5.923

9.  Potential cellular conformations of the CCN3(NOV) protein.

Authors:  Stanimir Kyurkchiev; Herman Yeger; Anne - Marie Bleau; Bernard Perbal
Journal:  Cell Commun Signal       Date:  2004-09-10       Impact factor: 5.712

Review 10.  Avian myeoloblastosis virus (AMV): only one side of the coin.

Authors:  Bernard Perbal
Journal:  Retrovirology       Date:  2008-06-16       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.